Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
NCT05028348 trial: what clinicians have said so far
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
- NCT05028348 ↗
- Active, not recruiting
- European Myeloma Network B.V.
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NCT05028348 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT05028348 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Selinexor; Elotuzumab; Pomalidomide; Dexamethasone Oral
- Arms
- Selinexor, pomalidomide and dexamethasone (SPd) · Experimental
- Elotuzumab, Pomalidomide and Dexamethasone (EloPd) · Active comparator
- Enrollment
- 117
- Primary outcomes
- Progression-free survival (PFS)
- Sponsor
- European Myeloma Network B.V. with Karyopharm Therapeutics Inc
- Start
- Apr 19, 2022
- Primary completion
- Mar 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05028348 · updated Dec 4, 2025